Neuromuscular Disorders Market Report 2026

Neuromuscular Disorders Market Overview

• Neuromuscular Disorders market size has reached to $8.31 billion in 2025 • Expected to grow to $12.07 billion in 2030 at a compound annual growth rate (CAGR) of 7.7% • Growth Driver: Rising Demand For Personalized Medicine Fueling The Growth Of The Market Due To Targeted, Patient-Specific Therapies • Market Trend: Expansion Of Gene Therapy Options Improves Treatment Access Across Age Groups • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Neuromuscular Disorders Market?

Neuromuscular disorders are a group of medical conditions that affect the nerves and muscles, leading to weakness, loss of movement, or impaired function. They occur when communication between the nervous system and muscles is disrupted due to genetic, autoimmune, or degenerative causes. These disorders often progress over time and require ongoing medical management, therapy, and supportive care. The main disease types of neuromuscular disorder include spinal muscular atrophy (SMA), amyotrophic lateral sclerosis (ALS), Duchenne muscular dystrophy (DMD), myasthenia gravis, and others. Spinal muscular atrophy (SMA) refers to a genetic disorder characterized by the loss of motor neurons, leading to progressive muscle weakness and atrophy, and requires targeted clinical management to improve patient outcomes. The variety of product types including pharmaceuticals, biologics, diagnostic tools, and assistive devices. The routes of administration such as oral, injectable, and others. The treatment approaches encompass gene therapy, drug therapy, RNA-based therapy, enzyme replacement therapy, physical therapy and rehabilitation, as well as respiratory care.

What Is The Neuromuscular Disorders Market Growth Forecast?

The neuromuscular disorders market size is expected to see strong growth in the next few years. It will grow to $12.07 billion in 2030 at a compound annual growth rate (CAGR) of 7.7%. The growth in the forecast period can be attributed to rising patient advocacy and support group activities, growing demand for biologics and gene therapies, increasing recognition of neuromuscular disorders in pediatrics, rising government initiatives for rare disease management, and growing emphasis on home-based care and rehabilitation services. Major trends in the forecast period include advancement in gene-editing technologies for targeted therapies, innovation in RNA-based treatment platforms, integration of AI for faster neuromuscular diagnosis, advancement in stem-cell-based regenerative treatments, and innovation in wearable devices for continuous patient monitoring.

Global Neuromuscular Disorders Market Segmentation

1) By Disease Type: Spinal Muscular Atrophy (SMA), Amyotrophic Lateral Sclerosis (ALS), Duchenne Muscular Dystrophy (DMD), Myasthenia Gravis, Other Muscular Dystrophies 2) By Product Type: Pharmaceuticals, Biologics, Diagnostic Tools, Assistive Devices 3) By Route of Administration: Oral, Injectable, Other Route of Administrations 4) By Treatment: Gene Therapy, Drug Therapy, RNA-Based Therapy, Enzyme Replacement Therapy, Physical Therapy And Rehabilitation, Respiratory Care Subsegments: 1) By Spinal Muscular Atrophy: SMA Type 1, SMA Type 2, SMA Type 3, SMA Type 4, SMA with Respiratory Distress (SMARD) 2) By Amyotrophic Lateral Sclerosis: Sporadic ALS, Familial ALS, Limb-Onset ALS, Bulbar-Onset ALS, Respiratory-Onset ALS 3) By Duchenne Muscular Dystrophy: Early-Onset DMD, Late-Onset DMD, Exon Deletion Mutations, Exon Duplication Mutations, Point Mutations 4) By Myasthenia Gravis: Generalized Myasthenia Gravis, Ocular Myasthenia Gravis, Seropositive MG, MuSK-Positive MG, Seronegative MG 5) By Other Muscular Dystrophies: Becker Muscular Dystrophy (BMD), Limb-Girdle Muscular Dystrophy (LGMD), Facioscapulohumeral Muscular Dystrophy (FSHD), Congenital Muscular Dystrophies, Myotonic Dystrophy

What Is The Driver Of The Neuromuscular Disorders Market?

The rising demand for personalized medicine is expected to propel the growth of the neuromuscular disorders market going forward. Personalized medicine is a medical approach that involves tailoring treatments to individual patients based on their genetic, environmental, and lifestyle factors to optimize outcomes and improve care. The demand for personalized medicine is increasing due to advancements in genomic technologies, which enable the precise identification of genetic variations and tailored treatments for individuals. Personalized medicine enhances neuromuscular disorder management by tailoring treatments based on individual genetic, molecular, and physiological profiles. It improves patient outcomes by enabling targeted therapies, optimizing efficacy, and minimizing adverse effects. For instance, in February 2024, according to the Personalized Medicine Coalition (PMC), a US-based nonprofit organization, the U.S. Food and Drug Administration (FDA) approved 26 new personalized medicines in 2023, a significant increase from the 12 approved in 2022. Therefore, the rising demand for personalized medicine is driving the growth of the neuromuscular disorders industry.

Key Players In The Global Neuromuscular Disorders Market

Major companies operating in the neuromuscular disorders market are AbbVie Inc., Novartis AG, Takeda Pharmaceutical Company Limited, The Trustees of the University of Pennsylvania, Biogen Inc., Sarepta Therapeutics Inc., argenx SE, PTC Therapeutics Inc., Catalyst Pharmaceuticals Inc., Mayo Clinic Laboratories, Fulgent Genetics Inc., Dyne Therapeutics Inc., The Regents of the University of California, GeneDx LLC, PepGen Inc., Centogene N.V., Scholar Rock Holding Corporation, Solid Biosciences Inc., Vita Therapeutics Inc., NMD Pharma A/S, Cytokinetics Incorporated, Sudo Biosciences Inc.

Global Neuromuscular Disorders Market Trends and Insights

Major companies operating in the neuromuscular disorders market are focusing on developing advanced treatments, such as gene replacement therapies, to address the underlying genetic causes of conditions such as Duchenne muscular dystrophy and spinal muscular atrophy. Gene replacement therapy refers to engineered biological products that deliver functional copies of defective genes to restore or improve muscle function in patients with inherited neuromuscular conditions, offering a potential one‑time treatment that reduces the need for long‑term chronic therapy. For instance, in November 2025, Novartis, a Switzerland‑based pharmaceuticals company, received the US Food and Drug Administration (FDA) approval for Itvisma (onasemnogeneabeparvovec-brve), the first and only gene replacement therapy for the treatment of children two years of age and older, teens, and adults with spinal muscular atrophy (SMA) who have a confirmed mutation in the survival motor neurone 1 (SMN1) gene. It is specifically made to treat the genetic underlying cause of SMA with a single, fixed dosage that doesn't require body weight or age adjustments. Itvisma can enhance motor function by substituting the SMN1 gene, which may lessen the requirement for long-term medication used in conjunction with other current treatments for this population.

What Are Latest Mergers And Acquisitions In The Neuromuscular Disorders Market?

In July 2023, Novartis AG, a Switzerland‑based pharmaceutical company, acquired DTx Pharma Inc. for an undisclosed amount. Through this acquisition, Novartis enhanced its RNA‑based therapeutic capabilities by adding DTx’s proprietary FALCON siRNA platform and advancing early‑stage programs targeting neuromuscular disorders such as Charcot‑Marie‑Tooth disease type 1A. DTx Pharma Inc. is a US‑based biotechnology company developing siRNA therapies for neurological and neuromuscular indications

Regional Insights

North America was the largest region in the neuromuscular disorders market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Neuromuscular Disorders Market?

The neuromuscular disorders market consists of revenues earned by entities through diagnostic testing, therapeutic interventions, genetic counseling, rehabilitation therapy, and long-term patient management. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Neuromuscular Disorders Market Report 2026?

The neuromuscular disorders market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the neuromuscular disorders industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.